23 filings · most recent first
REGN 8-K Filings
Regeneron Reports Strong Q2 2026 Financial Results With Revenue Growth And
Regeneron Pharmaceuticals Expects Q2 2026 Earnings Hit From Iprd Charge
Regeneron Pharmaceuticals Announces Results Of 2026 Annual Meeting Of
Regeneron Reports Strong Q1 2026 Financial Results And Authorizes New Share
Regeneron Pharmaceuticals Announces Expected Q1 2026 Iprd Charge
Regeneron Reports Q4 And Full Year 2025 Financial Results
Regeneron Provides Q4 2025 Corporate Update Financial Outlook And Charges
Regeneron Reports First Quarter 2025 Financial Results And Pipeline Updates
Regeneron Initiates Quarterly Dividend And Expands Share Repurchase Program
Regeneron Reports Strong Q3 2024 Results With 11 Revenue Growth And Dupixent
Regeneron Reports Strong Q2 2024 Financial Results With Revenue Growth And
Regeneron Pharmaceuticals Reports Q1 2024 Financial Results And Business Updates
Regeneron Pharmaceuticals Reports Q4 2023 Financial Results
Regeneron Pharmaceuticals Announces Acquired Iprd Charge
Regeneron Pharmaceuticals Shareholder Voting Results Announced
Regeneron Provides Business Updates At Jp Morgan Healthcare Conference
Regeneron Pharmaceuticals Expects 56M Iprd Charge For Q3 2024
Regeneron Pharmaceuticals Q2 2024 Financial Results Estimate
Regeneron Pharmaceuticals Shareholder Votes On 2024 Annual Meeting Proposals
Regeneron Pharmaceuticals Appoints New Cfo And Controller
Regeneron Pharmaceuticals Corporate Update On Q4 2023 Financial Results
Regeneron Announces Third Quarter 2025 Financial Results And Business Update
Regeneron Pharmaceuticals Reports Strong Second Quarter 2025 Results And